Are Providers Shifting from NTF to Fosfomycin for Inpatient UTI? Big Data Reveals Small Shifts.

Kalpana Gupta, MD, MPH 1,3, Matthew B. Goetz, MD4, Makoto Jones MD, MS5,6, Judith Strymish, MD1,2

1 VA Boston Healthcare System, West Roxbury, MA, 2 Harvard Medical School, Boston, MA, 3 Boston University School of Medicine, Boston, MA Veterans Affairs, 4 Greater Los Angeles Healthcare System, Los Angeles, CA, 5 Ideas Center VA Salt Lake City Health Care System, Salt Lake City, UT; 6 University of Utah School of Medicine, Salt Lake City, UT

Background

- Fosfomycin (FOS) and nitrofurantoin (NTF) are IDSA guideline approved drugs for acute cystitis in women.
- However, their activity against multi drug resistant gram negatives may be driving increased use among inpatients with more complicated UTI.
- We evaluated trends in inpatient prescribing of these UTI-specific agents in the predominantly male population of the national VA system over a 7 year period.

Methods

- All inpatient bar coded administrations for FOS and NTF at every VA facility nationwide from 2011-2017 were captured through a data analytics platform which extracts data from the VA Data warehouse.
- Antibiotic days of therapy and rates per 1000 patient days (DOT/1000CD) were extracted by year and compared using Mantel-Haenszel chi square for linear trend (MH OR).
- Demographics were captured via administrative data.

Results

- Prescriptions from over 65 million patient days spanning 7 years and all inpatient units in 129 VA facilities were included.
- Approximately 90% of patients were male with a mean age range of 55-64 years.
- Fosfomycin use increased from 128 prescriptions in 2011 to a high of 1230 in 2016 and 1003 in 2017 (Figure).
- At the maximum in 2016, prescription rates increased almost 10 fold compared to 2011 (MH OR 9.8, p<.001).
- Nitrofurantoin prescriptions declined from 26,590 in 2011 to 19,343 in 2017. Rates decreased 25% from 2.8 – 2.1, MH OR 0.75, p<.001.
- In 2017, fosfomycin and nitrofurantoin usage rates were highest in Rehabilitation/Spinal Cord Units (Table).

Conclusions

- In this large nationwide cohort, fosfomycin use increased almost 10 fold among predominantly male inpatients while nitrofurantoin use declined slightly.
- Nitrofurantoin is still used orders of magnitude more than fosfomycin, even after adjusting for extended days of activity of fosfomycin.
- Both agents retain activity against many MDR GNRS but differences in efficacy, tissue penetration, familiarity and availability likely influence the choice for oral UTI-specific treatment.

<table>
<thead>
<tr>
<th>2017 Data</th>
<th>ICU</th>
<th>MEDSUG</th>
<th>NH</th>
<th>PSYCH</th>
<th>REHAB/SCI</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOS DOT/1000 CD</td>
<td>0.06</td>
<td>0.15</td>
<td>0.07</td>
<td>0.03</td>
<td>0.73</td>
</tr>
<tr>
<td>NTF DOT/1000 CD</td>
<td>0.56</td>
<td>1.46</td>
<td>2.41</td>
<td>2.55</td>
<td>9.35</td>
</tr>
<tr>
<td>FOS Days</td>
<td>28</td>
<td>382</td>
<td>229</td>
<td>28</td>
<td>315</td>
</tr>
<tr>
<td>NTF Days</td>
<td>251</td>
<td>3699</td>
<td>7826</td>
<td>2634</td>
<td>4013</td>
</tr>
</tbody>
</table>

![National Trends in Inpatient Fosfomycin and Nitrofurantoin Usage](chart.png)